Clinical trial
Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total…
NCT00454298 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00454298 |
|---|---|
| Title | Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Regimen, Parallel-Group Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGG-523 Administered Orally to Subjects With Severe Osteoarthritis |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Osteoarthritis |
| Intervention type | Drug |
| Interventions | AGG-523 (Aggrecanase Inhibitor) |
| Enrollment | 2 |
| Start date | May 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Mar 30, 2007 |
| Last update posted | Jul 29, 2009 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: